Deborah M. Stephens

Deborah M. Stephens, DO

Languages spoken: English, Spanish

Academic Information

Departments Adjunct - Internal Medicine

Divisions: Hematology & Hematologic Malignancies

Languages Spoken: English, Spanish


Deborah Stephens, DO joined the Division of Hematology and Hematologic Malignancies as an Assistant Professor in 2014. She completed her internal medicine residency at Cleveland Clinic and fellowship training at Ohio State University. Dr. Stephens’s clinic focuses on patients with chronic lymphocytic leukemia (CLL) and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL.. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials there. Her research has been widely published in influential journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. She is a member of the editorial board for the Journal of Clinical Oncology. On a national level, she is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is the Physician Leader of the SWOG CLL Working Group Committee, which is a group of CLL experts from academic centers around the country who plan and implement national clinical trials to improve the standard-of-care for CLL patients across the country. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrate her deep commitment to improve the care of patients with CLL and lymphoma.

Education History

Undergraduate The University of Iowa
 BS
Professional Medical Kansas City University of Medicine
 DO
Residency Cleveland Clinic
 Resident
Residency The Ohio State University
 Resident
Fellowship The Ohio State University Medical Center
 Chief Fellow

Selected Publications

Journal Article

  1. Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC (2015). Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol, 90(11), 967-9. (Read full article)
  2. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM (2017). PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood, 130(2), 221-228. (Read full article)
  3. Stephens DM (2017). Brentuximab: is it time for a new "B" in ABVD? Blood, 130(11), 1281-1282. (Read full article)
  4. Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2013). Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype. Blood, 122(21), 2872.
  5. Rogers KA, Salem G, Stephens DM, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Huang Y, Ruppert AS, Jones J (2015). A single-institution retrospective cohort study of patients treated with R-EPOCH for Richter's transformation of chronic lymphocytic leukemia. Blood, 126(23), 2951.
  6. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd J (2016). Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. Blood, 128(22), 638.
  7. Haverkos BM, Schowinksy J, Kaplan J, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Flowers MED, Fensky TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia MH, Brown S, Armand P, Merryman RW, Bachanova V, Stephens DM, Nakamura R, Gutman JA, Devine S (2016). Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. Blood, 128(22), 1163.
  8. Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg J (2019). Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 134(15), 1238-1246. (Read full article)
  9. Stephens DM, Byrd J (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood, 133(12), 1298-1307. (Read full article)
  10. Stephens D (2019). Highs and lows of minimal residual disease in CLL. Blood, 133(5), 386-388. (Read full article)
  11. Stephens D (2019). Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia. Blood, 134(20), 1691-1696. (Read full article)
  12. Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman R (2020). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, 135(15), 1204-1213. (Read full article)
  13. Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda W (2021). Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 137(24), 3327-3338. (Read full article)
  14. Stephens DM, Byrd J (2021). Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood, 138(13), 1099-1109. (Read full article)
  15. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda W (2021). Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood, 139, 1794-1806. (Read full article)
  16. Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell C (2021). Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood, 139, 413-423. (Read full article)
  17. Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham J (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park, N.Y.), 30(11), 970-4, 980-1, C3. (Read full article)
  18. Stephens DM, Byrd J (2012). Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. Oncology (Williston Park, N.Y.), 26(11), 1044-54. (Read full article)
  19. Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema N (2015). Jumping translocations, a novel finding in chronic lymphocytic leukaemia. British journal of haematology, 170(2), 200-7. (Read full article)
  20. Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard J (2017). Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. British journal of haematology, 179(5), 739-747. (Read full article)
  21. Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Jones J (2018). A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. British journal of haematology, 180(2), 259-266. (Read full article)
  22. Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips T (2019). Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. British journal of haematology, 186(2), 255-262. (Read full article)
  23. Mickelson DM, Hatem S, and Copelan (2010). Granulocyte Simulating-Colony Factor-Associated Splenic Artery Rupture. Leukemia & lymphoma, 51(2), 335-337.
  24. Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, Copelan E (2011). Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone marrow transplantation, 46(1), 84-9. (Read full article)
  25. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, and Byrd J (2012). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 97(3), 423-427.
  26. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd J (2012). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 97(3), 423-7. (Read full article)
  27. Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, Byrd J (2021). Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica, 106(11), 2845-2852. (Read full article)
  28. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman R (2021). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, 107, 1335-1346. (Read full article)
  29. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney D Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. . Journal of the National Cancer Institute,
  30. Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith S (2016). Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. Journal of clinical oncology, 34(25), 2997-3004. (Read full article)
  31. Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD 3rd, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg J (2020). Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of clinical oncology, 38(26), 3003-3011. (Read full article)
  32. Koffman B, Mato A, Byrd J, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids M, Pagel JM, Shadman M (2020). A survey of CLL experts opinion on management of patients during the COVID-19 pandemic. Journal of clinical oncology, E199-E203..
  33. Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn J (2013). Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leukemia research, 37(10), 1195-9. (Read full article)
  34. Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd J (2014). Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia, 28(6), 1365-8. (Read full article)
  35. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman R Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: Pooled analysis of 762 patients. 2021 Apr. Accepted for publication. Leukemia,
  36. Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman J (2021). Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 35(11), 3201-3211. (Read full article)
  37. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman R (2016). Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine, 374(4), 323-32. (Read full article)
  38. Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV (2021). The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clinical cancer research,
  39. Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov A (2021). The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clinical cancer research, 27(17), 4814-4824. (Read full article)
  40. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar (2017). Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15, 1414-1427.
  41. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer MA, Sundar H. (2020). Chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 4.2020, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 18(2), 185-217.
  42. Havard R, Stephens D (2018). Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. Current hematologic malignancy reports, 13(6), 534-542. (Read full article)
  43. Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd J (2014). Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. mAbs, 6(3), 749-55. (Read full article)
  44. Luo C, Deng Z, Li L, Clayton F, Chen AL, Wei R, Miles R, Stephens DM, Glenn M, Wang X, Jensen PE, Chen (2016). Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. Oncotarget, 7(11), 12806-22. (Read full article)
  45. Stephens DM, Spurgeon S (2015). Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Therapeutic advances in hematology, 6(5), 242-52. (Read full article)
  46. Gordon MJ, Sitlinger A, Salous T, Alqahtani H, Churnetski M, Rivera X, Wisniewski P, Cohen J, Patel K, Shadman M, Choi M, Hill B, Stephens DM, Persky D, Brander D, Danilov AD (2020). A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: results from a multicenter retrospective cohort study. Leukemia research and treatment, 89,
  47. Stephens DM, Goodrich A (2016). Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. Journal of the advanced practitioner in oncology, 7(3), 314-317. (Read full article)
  48. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd J (2019). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood advances, 3(9), 1553-1562. (Read full article)
  49. Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov A (2021). Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplantation and cellular therapy, 27(1), 46-52. (Read full article)
  50. Abbott J, Corean J, Snyder AM, Florell SR, Miles R, Stephens DM, Wada D Clinical and histologic spectrum of cutaneous hypersensitivity reactions in CLL/SLL patients with identification of T-cell papulosis of B-cell malignancy as a distinct subset. 2021 Mar. Submitted for review.
  51. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp N (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. 5, 189-199. (Read full article)
  52. Hu R, Wei W, Mian A, Gonter-Aubin K, Kabel C, Mato A, Stephens DM, Hanlon A, Khajavian S, Shadman M, Brander D, Madanat Y, Park JH, Tallman M, Pinilla-Ibarz J, Hill B (2022). Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. European journal of haematology, 108(5), 379-382. (Read full article)
  53. Black GS, Huang X, Qiao Y, Tarapcsak S, Rogers KA, Misra S, Byrd JC, Marth GT, Stephens DM, Woyach J (2022). Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients. Blood, 140(4), 401-405. (Read full article)
  54. Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, Allen P, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Bailey NA, Pagel JM, Ramchandren (2021). Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clinical lymphoma, myeloma & leukemia, 22, e435-e442. (Read full article)
  55. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach J (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical cancer research, 28(15), 3242-3247. (Read full article)
  56. Shah H, Stephens D, Seymour J, Maddocks (2021). Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 41, 1-18. (Read full article)
  57. Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg J (2022). Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica, (Read full article)
  58. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar (2022). NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. Journal of the National Comprehensive Cancer Network, 20(6), 622-634. (Read full article)
  59. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar (2020). Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18(2), 185-217. (Read full article)
  60. Shouse G, Kaempf A, Gordon MJ, Artz AS, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski SM, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov A (2023). A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma. Blood advances, (Read full article)
  61. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney D (2023). Secondary malignancies in non-Hodgkin lymphoma survivors: 40¿years of follow-up assessed by treatment modality. Cancer medicine, 12(3), 2624-2636. (Read full article)
  62. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao (2023). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leukemia & lymphoma, 64(2), 356-363. (Read full article)
  63. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney D (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Advances in radiation oncology, 7(6), 101035. (Read full article)
  64. Ujjani CS, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, O'Brien SM, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling AL, Tu B, Sorensen T, Launchbury KM, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson P (2022). Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood advances, (Read full article)
  65. Zurko JC, Nizamuddin I, Epperla N, David KA, Cohen JB, Moyo T, Ollila TA, Hess BT, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik JT, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald LA, Galvez C, Ma S, Winter JN, Pro B, Gordon LI, Danilov AV, Stephens DM, Shah NN, Kenkre VP, Barta SK, Torka P, Shouse G, Karmali (2022). Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood advances, 7(12), 2657-2669. (Read full article)
  66. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline (2023). Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood advances, (Read full article)
  67. Johnson PC, Woyach JA, Ulrich A, Marcotte V, Nipp RD, Lage DE, Nelson AM, Newcomb RA, Rice J, Lavoie MW, Ritchie CS, Bartlett N, Stephens DM, Ding W, Owen C, Stone R, Ruppert AS, Mandrekar SJ, Byrd JC, El-Jawahri A, Le-Rademacher J, Rosko (2023). Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. Journal of geriatric oncology, 14(6), 101538. (Read full article)
  68. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda W (2023). Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet (London, England), (Read full article)
  69. Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour E (2023). The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA network open, 6(6), e2316642. (Read full article)
  70. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. Haematologica, 108(11), 3025-3032. (Read full article)
  71. Terpos E, Branagan AR, García-Sanz R, Trotman J, Greenberger LM, Stephens DM, Morel P, Kimby E, Frustaci AM, Hatjiharissi E, San-Miguel J, Dimopoulos MA, Treon SP, Leblond (2023). Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management. Seminars in hematology, 60(2), 107-112. (Read full article)

Review

  1. Stephens DM, Byrd JC (2020). Next-Generation Bruton Tyrosine Kinase Inhibitors. [Review]. Am J Clin Oncol, JCO2001594.
  2. Stephens DM, Byrd J (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. . Blood, 133(12), 1298-1307.
  3. Stephens D (2019). Highs and lows of minimal residual disease in CLL. Blood, 133(5), 386-388.
  4. Stephens D (2019). Venetoclax and obinutuzumab for front-line treatment of chronic lymphocytic leukemia. Blood, 134(20), 1691-1696.
  5. Stephens DM, Byrd J Resistance to Bruton’s Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies Next-Generation Bruton Tyrosine Kinase Inhibitors. Accepted for publication. Blood,
  6. Mickelson DM, Mady E, and Teng (2009). A 43 year-old woman with chest pressure: a review of hypercoagulable states. Cleveland Clinic journal of medicine, 76(3), 191-8.
  7. Stephens DM, Byrd J (2013). Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. Hematology/oncology clinics of North America, 27(2), 303-27. (Read full article)
  8. Shah H, Stephens DM, Seymour J, Maddocks Incorporating novel targeted and immunotherapeutic agents in treatment of B-cell lymphomas. 2021 Feb. Accepted for publication. Journal of clinical oncology,
  9. Stephens DM, Byrd J (2012). Chronic lymphocytic leukemia with del(17p13.1): A distinct clinical subtype requiring novel treatment approaches. Oncology, 11, 1044-1054.
  10. Stephens DM, Byrd J (2012). Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. Oncology, 26(11), 1044-1054.
  11. Voorhies BN, Stephens D (2017). What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?. Current treatment options in oncology, 18(2), 12. (Read full article)
  12. Shadman M, Stephens D (2020). Debate: What is optimal first-line therapy for chronic lymphocytic leukemia?. Journal of the National Comprehensive Cancer Network, 18(7.5), 993-997.
  13. Harvard R, Stephens D (2018). Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. Current hematologic malignancy reports, 13(6), 534-542.
  14. Stephens DM, Sweetenham J (2015). Clinical controversies of double-hit lymphoma. American journal of hematology/oncology, 11(4), 10-16.
  15. Stephens DM, Goodrich A (2016). Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. Journal of the advanced practitioner in oncology, 7(3), 314-317.
  16. Stephens DM, Byrd J (2012). Ask the hematologists: Is there a standard of care for treating older patients with chronic lymphocytic leukemia?. 9(4), 4.
  17. Stephens DM, Smith S (2018). Diffuse large B-cell lymphoma-Who should we FISH?. 2, 2616-2695.

Conference Proceedings

  1. Stephens DM, Cheney CM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tidandapani S, Muthusamy N, and Byrd J (2013). Ocaratuzumab, a proposed effective and convenient alternative for treatment of chronic lymphocytic leukemia.
  2. Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd J (2013). Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype.
  3. Stephens DM, Starodub AN, Byrd JC, Wegener, WA, Horne H, Goldenberg, DM, Christian B (2015). Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a phase I first-in-man study in hematologic malignancies.
  4. Stephens DM, LeBlanc ML, Li H, Miller TP, Puvvada SD, Persky D, Friedberg J, Smith S (2015). Continued risk of relapse independent of treatment modality in limted stage diffuse large B-cell lymphoma: Final and long-term analysis of SWOG study S8736.
  5. Stephens DM, Ruppert AS, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Jones JA, Flynn JM, Grever MR, Hareema N, Muthusamy N, and Byrd J (2013). Predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
  6. Stephens DM, Maddocks K, Andritsos L, Baiocchi R, Jones J, Phelps M, Johnson AJ, Smith L, Grever MR, Byrd JC, and Flynn JM (2012). Phase I feasibility trial of cyclophosphamide, alvocidib (flavopiridol) and rituximab in patients with high-risk b-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
  7. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, and Byrd JC (2010). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.
  8. Mickelson D, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, and Copelan (2009). T-cell engraftment kinetics following myeloablative and nonmyeloablative regimens for allogeneic hematopoietic stem-cell transplantation.
  9. Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens DM, Nakumura R, Gutman J, Devine SM (2016). Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease.
  10. Stephens DM, Starodub AN, Byrd JC, Wegener, WA, Horne H, Goldenberg, DM, Christian BA (2016). Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a phase I first-in-man study in hematologic malignancies.
  11. Byrd JC, Jones JA, Furman RR, Stephens DM, Devereux S, Brown JR, Hillmen P, Hamdy AM, Wang MH, Patel P, Mittag D, Krantz M, Rothbaum W, Izumi R, O'Brien SM, Wierda WG (2016). Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, in previously untreated chronic lymphocytic leukemia.
  12. Byrd JC, Wierda W, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Charuworn P, Hamdy A, Izumi R, Patel P, Wan MH, Furman R (2017). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: Updated results from the phase 1/2 ACE-CL-001 Study.
  13. Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien SM, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillemen P, Pagel JM, Chen D, Hamdy A, Izumi R, Patel P, Wan MH, Jain N, Wierda W (2018). Acalabutinib in treatment-naive chronic lymphocytic leukemia: Updated results from phase 1/2 ACE-CL-001 study.
  14. Geer M, Shango M, Till B, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Roberts E, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips T (2017). Multicenter retrospective study of features and outcomes of patients with intravascular DLBCL treated at academic institutions within the United States.
  15. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd J (2016). Acalabrutinib monotherapy in patients with ibrutinib: results from the phase 1/2 ACE-CL-001 clinical study.
  16. Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens DM, Nakumura R, Gutman J, Devine S (2016). Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease.
  17. Wierda WG, Jones JA, Furman RR, Stephens DM, Devereux S, Brown JR, Hillmen P, Hamdy A, Fardis M, Tawashi M, Wang MH, Patel P, Mittag D, Krantz F, Rothbaum W, Izumi R, O'Brien S, Byrd J (2016). Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, in previously untreated chronic lymphocytic leukemia.
  18. Byrd JC, Wierda WG, Jones JA, O'Brien S, Brown JR, Schuh A, Hillmen P, Stephens DM, Gia P, Devereux S, Chaves J, Barrientos JC, Wan MH, Huang J, Covey T, Navarro T, Hamdy A, Furman R (2015). The Bruton tyrosine kinase (Btk) inhibitor ACP-196: Marked activity in relapsed/refractory CLL with a favorable safety profile.
  19. Koffman B, Dennison B, Kennard K, Furman R, Byrd J, Pagel J, Davids MS, Nabhan C, Kay N, Brander D, Siddiqi T, Hill B, Pinilla-Ibarz J, Cheson B, Rosen ST, Wierda WG, Stephens DM, Awan FT, Choi MY, Mato A (2018). A US-Based survey: The experiences and perspectives of 1147 chronic lymphocytic leukemia patients.
  20. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd J (2016). Acalabrutinib monotherapy in patients with ibrutinibi: results from the phase 1/2 ACE-CL-001 clinical study.
  21. Siddiqi T, Dorritie KA, Soumerai JD, Stephens DM, Dubovsky JA, Gillenwater HH, Gong L, Thorpe J, Yang L, Wierda W (2019). TRANSCEND 004 CLL: Minimal residual disease negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. .
  22. Karmali R, Abramson JS, Stephens DM, Barnes JA, Kaplan JB, Winter JN, Ma S, Petrich AM, Hochberg EP, Takvorian T, Nelson V, Gordon LI, Pro (2019). Ibrutinib maintenance following induction for untreated mantle cell lymphoma: Initial safety report. .
  23. Rogers KA, Wei L, Bhatt S, Jones D, Seymour E, Stephens DM, Ye C, Byrd JC, Woyach J (2019). A multicenter study of ibrutinib resistance development and intervention with venetoclax.
  24. Hamid MS, Rutherford SC, Kim S, Bartlett N, Kate-Malecek M, Watkins M, Maddocks K, Bond D, Feldman T, Magarelli G, Advani R, Spinner M, Ahmed S, Stephens DM, Allen P, Patel K, Tees MT, Karmali R, Cheson B, Yazdy MS, Link B, Strouse C, Pagel JM, Ramchandren (2019). Risk adapted approach for PET-2 positive Hodgkin lymphoma in the real world setting. .
  25. Karmali R, Abramson J, Stephens DM, Barnes J, Kaplan J, Winter J, Ma S, Gao J, Petrich A, Hochberg E, Takvorian T, Kuhr F, Nelson V, Gordon LI, Pro (2019). Interim safety, response and MRD evaluation in mantle cell lymphoma (MCL) patients treated with frontline intensive induction chemotherapy followed by ibrutinib maintenance. .
  26. Byrd JC, Wierda W, Schuh, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman R (2019). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: 45-Month follow-up of a phase 2 study. .
  27. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Dubovsky JA, Rytlewski J, Yang L, Wierda W (2019). Rapid undetectable MRD responses in patients with relapsed/refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treated with lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T Cell product: Updated results from TRANSCEND CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib. .
  28. Kittai A, Gordon M, Mian A, Fitzgerald L, Bishop J, Stephens DM, Nagle S, Hill B, Danilov (2019). Comorbidities predict inferior survival in patients receiving CAR T-cell therapy for relapsed/refractory DLBCL: A multicenter retrospective analysis. .
  29. Woyach JA, Stephens DM, Flinn I, Bhat S, Savage R, Chai F, Eathiraj S, Granlund L, Szuszkiewicz L, Schwartz B, Byrd J (2019). Final results of a phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-Cell lymphoid malignancies.
  30. Persky DO, Li H, Stephens DM, Park SI, Bartlett N, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Friedberg J (2019). PET-Directed therapy for patients with limited-stage diffuse large B-Cell lymphoma - Results of Intergroup NCTN Study S1001. .
  31. Stephens, DM, Huang Y, Ruppert AS, Agyeman A, Hu B, Turner N, Vadeboncoeur R, Rogers K, Bhat S, Basem W, Jaglowski SM, Hockman H, Glenn MJ, Lapalombella R, Byrd JC, Woyach (2019). Selinexor combined with ibrutinib demonstrates tolerability and efficacy in advanced B-cell malignancies: A phase I study. .
  32. Byrd J, Woyach J, Furman R, Martin P, O¿B.rien S, Brown J, Stephens D, Barrientos J, Devereux S, Hillmen P, Pagel J, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda (2019). Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase 2 study demonstrating durable remission and long-term tolerability.    .
  33. Wierda WG, Dorritie KA, Munoz J, Stephens DM, Solomon S, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Siddiqi (2020). TRANSCEND CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product, in combination with ibrutinib for patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). .
  34. Gordon M, Kaempf A, Sitlinger A, Salous T, Alqahtani H, Churnetski MC, Wisniewski P, Rivera X, Patel K, Persky D, Cohen JB, Choi M, Hill BT, Shadman M, Stephens DM, Brander D, Park B, Danilov A (2020). The chronic lymphocytic leukemia comorbidity index (CLL-CI) predicts survival and tolerance of ibrutinib therapy in patients with CLL: A multicenter retrospective cohort study. .
  35. Orellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Watkins M, Kahl B, Spinner M, Advani R, Voorhees T, Snow A, Grover N, Ayers A, Romacik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Potro C, Olszewski A, Ayers E, Landsburg D, Echaier B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portel (2020). Prophylaxis during front-Line therapy in aggressive non-Hodgkin lymphomas: Real-world outcomes and practice patterns from 19 US academic institutions. .
  36. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Wierda W (2020). Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of TRANSCEND CLL 004, including high-risk and ibrutinib-treated patients.
  37. Wierda WG, Dorritie KA, Munoz J, Stephens DM, Solomon S, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Siddiqi (2020). TRANSCEND CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  38. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Baek M, Lezhava T, Kuptsova-Clarkson N, Moslehi J, Furman R (2020). Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia.
  39. Karmali R, Abramson JS, Stephens DM, Barnes J, Kaplan J, Winter JN, Ma S, Gao J, Petrich A, Hochberg E, Takvorian T, Kuhr F, Nelson V, Gordon LI, Pro, (2020). Ibrutinib maintenance (I-M) following frontline intensive induction in mantle cell lymphoma (MCL): assessment of efficacy, safety and changes in minimal residual disease.
  40. Blachly JS, Lamanna N, Stephens DM, Ye CJ, Niesman M, Zhang K, Woyach J (2020). Initial results from a phase 1 dose escalation study evaluating MS-553, a novel, selective PKC-beta inhibitor, in relapsed or refractory CLL/SLL patients.

Commentary

  1. Stephens D (2017). Brentuximab: is it time for a new "B" in ABVD?. Blood, 130(11), 1281-1282.
  2. Stephens D (2016). Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia: An Archaic Intervention or a Necessary Evil?. Oncology (Williston Park, N.Y.), 30(6), 539-40. (Read full article)

Case Report

  1. Laggis C, Miles R, Stephens DM, Duffy K, Bowen A, Wada (2019). Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report. Journal of cutaneous pathology, 46(7), 538-541. (Read full article)
  2. Juster-Switlyk K, Smith AG, Kovacsovics T, Stephens D, Glenn M, Palmer CA, Quigley EP 3rd, Kolb (2017). MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk. Neurology, 88(6), 603-604. (Read full article)
  3. Fitzgerald L, Stephens D (2020). Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. Clinical lymphoma, myeloma & leukemia, 20(4), e201-e204. (Read full article)
  4. Fitzgerald LA, Stephens D (2017). Seeing Double: A Rare Presentation of Non-Hodgkin Lymphoma. Annals of hematology & oncology, 4(6), 1155.
  5. Shah HR, Stephens D (2021). Is there a role for anti-CD20 antibodies in CLL?. Hematology. American Society of Hematology. Education Program, 2021(1), 68-75. (Read full article)

Editorial

  1. Stephens D (2021). Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?. Journal of clinical oncology, 39(31), 3419-3422. (Read full article)

Letter

  1. Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids MS, Pagel JM, Shadman M (2020). Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. [Letter to the editor]. Am J Hematol, 95(8), E199-E203. (Read full article)
  2. Stephens DM, Schoder H, Li H, Friedberg (2020). Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?. Journal of nuclear medicine, 61(11), 1695. (Read full article)
  3. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens D (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. American journal of hematology, 98(7), E172-E174. (Read full article)

Abstract

  1. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd J (2016). Acalabrutinib monotherapy in patients with ibrutinibi: results from the phase 1/2 ACE-CL-001 clinical study. Blood, 128(22), 638.
  2. Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberlye MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP (2017). Outcomes of adults, adolescents, and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R therapy: a multicenter retrospective analysis. Hematological oncology, 35(S2), 61-2.
  3. Stephens DM, Ruppert AS, Christian B, Jones J, Flynn JM, Porcu P, Baiocchi R, Byrd JC, Dotson EK, Crawford BS, and Blum K (2012). Toxicity in patients 65 years with dose adjusted REPOCH for untreated diffuse large B cell lymphoma. Journal of clinical oncology, 30(suppl), 15.
  4. Stephens DM, Ruppert AS, Christian B, Jones J, Flynn JM, Porcu P, Baiocchi R, Byrd JC, Dotson EK, Crawford BS, Blum K (2012). Toxicity in patients ¿ 65 years with dose adjusted REPOCH for untreated diffuse large B cell lymphoma. 30(suppl), 15.

News & Podcasts

Huntsman Cancer Institute News